Tetrabenazine Dose (XENAZINE Dose)

The tetrabenazine dose someone can safely take is one of the few in medicine where the label itself asks for a genetic test first. Above 50 mg a day, CYP2D6 genotyping decides the ceiling. Here is what that rule means in practice, which medicines change it, and what to watch for along the way.

Tetrabenazine was approved in the United States in 2008 for Chorea associated with Huntington’s disease, a neurological condition that causes involuntary, unpredictable movements in the face, hands, and feet. It is also used off-label in the treatment of Hemiballismus, a rare neurological disorder that causes involuntary, forceful movements of the limbs on one side of the body, Tardive Dyskinesia, a chronic movement disorder that causes involuntary muscle movements in the face, body, and limbs, and Tourette Syndrome which is a is a neurological disorder that causes involuntary movements and sounds called tics.

While medications help control diseases, they can worsen the conditions or create new issues if not administered properly. While doctors start small and gradually increase the doses to learn the least working dose, the FDA-approved drug label states that any Tetrabenazine dose above 50 mg per day calls for CYP2D6 genotyping first, in other words a look at your genome (DNA).

Any drug you consume is metabolized by a specific enzyme in the body, in the case of Tetrabenazine, CYP2D6 is responsible for the metabolization.

Tetrabenazine Administration

Tetrabenazine is available in tablet form for oral administration and can be taken with or without food. The initial recommended dose is 12.5 mg once daily. Based on patient response and tolerance, the dosage may be increased by 12.5 mg every week. Typically, the dose is increased to 25 mg per day in the second week, administered as 12.5 mg twice daily.

Further adjustments can be made, with the total daily dose divided into two or three administrations, not exceeding a maximum of 100 mg per day. The label sets a lower ceiling, 50 mg per day, for people who are CYP2D6 poor metabolizers. Dose adjustments should be individualized, taking into account factors such as the severity of symptoms, patient response, and the presence of any adverse effects.

According to the FDA label, “Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer.”

Chorea and its Symptoms

Chorea is a movement disorder characterized by involuntary, unpredictable body movements. Some of the symptoms include:

• Restlessness (fidgeting): Individuals may exhibit twitching, jerking, or twisting movements of the arms, legs, and face that are not purposeful.
• Milkmaid’s grip: This refers to the involuntary squeezing and releasing of the hands repeatedly when attempting to maintain a firm grip, resembling the motion of milking a cow.
• Difficulty swallowing: Some individuals may experience challenges in swallowing.
• Difficulty talking: Speech may be affected, leading to trouble speaking.
• Abnormal gait: Walking patterns may become irregular, and maintaining balance can be challenging.
• Muscle rigidity or contracture: Some individuals may experience muscle stiffness or contractures.

Common Age of Onset

The age of onset for chorea varies depending on its underlying cause. For instance, in Huntington’s disease, a common cause of chorea, symptoms typically begin between the ages of 30 and 50. However, chorea can manifest at any age, depending on the specific etiology.

Dose for Treating Chorea

The dosing of tetrabenazine for chorea is individualized based on factors such as the severity of symptoms, patient response, and tolerance. The initial dose is typically 12.5 mg once daily, with gradual increases by 12.5 mg each week. The total daily dose is divided into two or three administrations, with a maximum recommended dose of 100 mg per day. Regular monitoring is essential to adjust the dose appropriately and to manage any potential side effects.

Hemiballismus and its Symptoms

Hemiballismus is a rare movement disorder characterized by involuntary, violent, and wide-amplitude movements, typically affecting one side of the body. These movements are more intense than those seen in chorea and can significantly impair daily functioning.

Common Age of Onset

Hemiballismus can occur at any age but is more commonly observed in older adults. It often results from lesions in the subthalamic nucleus, frequently due to cerebrovascular events such as strokes.

Dose for Treating Hemiballismus

Tetrabenazine has been used off-label for the treatment of hemiballismus. The dosing regimen is similar to that used for chorea, starting with a low dose and gradually titrating based on patient response and tolerance. Given the limited specific studies on tetrabenazine for hemiballismus, treatment should be closely monitored by a healthcare professional experienced in managing movement disorders.

Tardive Dyskinesia and its Symptoms

Tardive dyskinesia (TD) is a movement disorder characterized by repetitive, involuntary movements, primarily affecting the face, lips, tongue, and extremities. Symptoms include:

• Facial grimacing: Uncontrolled facial expressions.
• Tongue movements: Protrusion or rolling of the tongue.
• Lip smacking or puckering: Involuntary lip movements.
• Rapid blinking: Increased frequency of eye blinking.
• Movements of the arms, legs, or trunk: Jerking or twisting motions.

These movements can interfere with daily activities and may persist even after discontinuation of the causative medication.

Common Age of Onset

TD can develop at any age but is more prevalent in older adults. The risk increases with prolonged use of antipsychotic medications, particularly typical antipsychotics.

Dose for Treating Tardive Dyskinesia

Tetrabenazine has been used in the treatment of TD, although it is not specifically approved for this indication. The dosing strategy involves starting at a low dose and gradually increasing based on patient response and tolerance. Close monitoring is essential due to the potential for side effects, including depression and parkinsonism.

Tourette Syndrome and its Symptoms

Tourette syndrome is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics. Symptoms include:

• Motor tics: Sudden, brief, repetitive movements such as eye blinking, facial grimacing, shoulder shrugging, or head jerking.
• Vocal tics: Unintended sounds, including throat clearing, grunting, or uttering words or phrases.

The severity and frequency of tics can vary over time and may be exacerbated by stress or excitement.

Common Age of Onset

Tourette syndrome typically manifests in childhood, with the average onset between ages 5 and 7. Males are more commonly affected than females.

Dose for Tourette Syndrome

Tetrabenazine has been used off-label to manage tics in Tourette syndrome.

How Does Tetrabenazine Work?

Tetrabenazine works by reducing the activity of specific neurotransmitters in the brain, particularly dopamine. Its primary mechanism involves inhibiting the vesicular monoamine transporter 2 (VMAT2), a protein that regulates the storage and release of dopamine in nerve cells. By depleting dopamine levels, tetrabenazine helps control abnormal movements associated with disorders like chorea, hemiballismus, and tardive dyskinesia.

Active Ingredient:

Tetrabenazine itself is the active ingredient, and it is quickly converted into dihydrotetrabenazine metabolites that carry much of its effect. CYP2D6 then breaks down those active metabolites, which is why your CYP2D6 status matters.

Effects on the Brain:

Decreases dopamine levels: This reduces hyperactive neural signaling, which is implicated in movement disorders.

Impact on other neurotransmitters: Tetrabenazine also influences serotonin and norepinephrine, though its effects on these systems are less pronounced than on dopamine.

Potential risks: Dopamine depletion may lead to symptoms of depression or parkinsonism in some individuals.

Potential Side Effects of Tetrabenazine

Tetrabenazine may cause side effects, varying by individual and influenced by dosage. Potential side effects include:

Common Side Effects:

• Fatigue or drowsiness
• Nausea
• Anxiety or restlessness
• Insomnia
• Depressed mood

Less Common but Serious Side Effects:

Suicidal thoughts or behaviors. Tetrabenazine carries a boxed warning for depression and suicidality in people with Huntington’s disease. If you or someone you care for has thoughts of self harm, call or text the 988 Suicide and Crisis Lifeline right away.

Parkinsonism-like symptoms (shaky or vibrating movements in the body, slowed movements, and stiffness).
Hypotension (low blood pressure)
Increased risk of QT prolongation, leading to potential heart rhythm issues

Monitoring Side Effects:

• Who needs closer watching: Anyone with a history of depression, suicidal thoughts, or a heart rhythm problem should be followed closely while taking tetrabenazine.
• Monitoring and Mitigation: Close monitoring of mental health and physical symptoms is essential, particularly in individuals with a history of depression or cardiac conditions.

Pharmacogenomics and Optimal Tetrabenazine Doses:

Pharmacogenomic testing often known as PGx testing shows how an individual may respond to certain medications. This gives you insights into your DNA that help doctors analyze what type of metabolizer you are, based on which they can tailor your medication accordingly. A non-invasive and at home PGx test by RPH LABS shows how your body may respond to 240+ medications. Tetrabenazine is metabolized by CYP2D6 and our report shall clearly show what type of CYP2D6 metabolizer you are.

Unsure how to book a PGx test or how this works? Here we have a step-wise process for you.

References:

• Pubmed
• Clevelandclinic

Disclaimer: This blog is only for informational purposes. Always consult a doctor before taking any medical action.

What a VMAT2 inhibitor does, and why the dose is delicate

Tetrabenazine is a VMAT2 inhibitor. VMAT2 is the pump that loads dopamine and related chemical messengers into storage vesicles inside a nerve ending. Block the pump and less dopamine gets packaged, so less is released when the nerve fires.

In chorea, dopamine signalling is effectively too loud. Turning the volume down reduces involuntary movement. The same action explains the trouble a VMAT2 inhibitor can cause, because dopamine also carries mood, motivation and movement initiation signals you want left alone.

That is the core tension in every tetrabenazine dose decision. Too little and movements are not controlled. Too much and you risk low mood, slowed movement, stiffness and sedation. There is no blood level test in routine use, so the dial is turned slowly against symptoms.

It also explains why a VMAT2 inhibitor is started low and raised in small weekly steps, as the original article describes. The goal is the lowest dose that controls movements, not the highest dose tolerated.

The CYP2D6 rule built into the tetrabenazine dose label

Tetrabenazine is converted by the body into active metabolites, and CYP2D6 does most of that work. Because CYP2D6 activity varies enormously between people, exposure to those active metabolites does too.

The FDA label handles this directly. Anyone who needs a tetrabenazine dose above 50 mg per day is to be genotyped for CYP2D6 first, to establish whether they are a poor metabolizer or an extensive metabolizer. It is one of the clearest examples of pharmacogenomics written into a prescribing instruction rather than left as a suggestion.

The result then sets a ceiling, not a recommended dose. Extensive and intermediate metabolizers may go higher, with the label capping the total daily amount at 100 mg and limiting how much can be given in a single dose. A poor metabolizer result brings both of those ceilings down.

Warfarin, codeine and several antidepressants appear in the FDA’s table of pharmacogenomic biomarkers in drug labeling for similar reasons, and tetrabenazine sits alongside them with CYP2D6. Your prescriber chooses where inside the allowed range you actually sit.

What a CYP2D6 poor metabolizer result means here

A CYP2D6 poor metabolizer carries two copies of the gene with little or no function. The enzyme is largely absent, so active metabolite levels build up and both benefit and harm arrive at lower milligram amounts.

For tetrabenazine, the label response to a CYP2D6 poor metabolizer result is a lower maximum daily dose and a lower maximum single dose. That is not a judgment about how well the drug will work; it is a statement that the same effect is reached with less drug.

CYP2D6 is genuinely complicated. Copy number varies, some people carry duplicated functional genes, and star allele combinations produce a range from poor metabolizer through ultrarapid. PharmVar is the reference catalogue that laboratories use to name these alleles consistently.

Because your DNA does not change, a CYP2D6 result is a one-time test. RPh Labs reports CYP2D6 on its at-home cheek swab kit alongside 19 other genes, with every report reviewed by a PharmD pharmacist. Our page on CYP2D6 inhibitors explains the other half of the picture.

Medicines that lower the tetrabenazine dose ceiling

Genotype is not the only thing that sets CYP2D6 activity. Some medicines block the enzyme so effectively that a normal metabolizer behaves like a poor one. This is called phenoconversion, and it matters more with tetrabenazine than with most drugs.

• Fluoxetine and paroxetine, both strong CYP2D6 inhibitors and both common antidepressants
• Bupropion, which is also a strong inhibitor and is often prescribed for mood or smoking cessation
• Quinidine
• Some other antidepressants and antipsychotics, which inhibit CYP2D6 more weakly but still count in combination

When a strong inhibitor is on board, the label applies the same lowered ceilings used for a poor metabolizer. So a tetrabenazine dose that was fine last month can become too much simply because an antidepressant was added, without anything else changing.

There are also outright contraindications worth knowing: monoamine oxidase inhibitors, reserpine, and significant liver impairment. Tell every prescriber and pharmacist that you take tetrabenazine before any new medicine is added, and check with them before stopping one as well, because removing an inhibitor shifts exposure the other way.

Tetrabenazine side effects that need a same-day call

Tetrabenazine carries a boxed warning for depression and suicidality in people with Huntington’s disease, and it is not used in someone who is actively suicidal or whose depression is untreated. This is the single most important item on the list of tetrabenazine side effects.

If you or a family member notices new or worsening low mood, hopelessness, loss of interest, agitation or any thought of self-harm, contact the prescriber the same day. In the US you can reach the 988 Suicide and Crisis Lifeline by call or text at any hour. In an emergency, call 911.

Other tetrabenazine side effects to report promptly include new stiffness or slowed movement, restlessness that will not settle, fainting or dizziness on standing, trouble swallowing, and a fast or irregular heartbeat, since the drug can prolong the QT interval. Fever with muscle rigidity and confusion needs urgent assessment.

Milder tetrabenazine side effects such as drowsiness, tiredness, nausea and trouble sleeping are common early and often improve. Keep a short daily note of mood, sleep and movement, because a pattern over two weeks tells a prescriber far more than a single impression at the appointment.

Where tetrabenazine fits among chorea treatment options

Tetrabenazine is not the only chorea treatment. Deutetrabenazine is a modified version of the same molecule designed to last longer in the body, and valbenazine is another VMAT2 inhibitor approved for tardive dyskinesia.

Those alternatives also interact with CYP2D6, so a genotype result keeps its value if therapy changes. Deutetrabenazine has its own dose ceiling for poor metabolizers, and valbenazine labelling addresses reduced doses for people with low CYP2D6 activity.

A full chorea treatment plan is rarely only a drug. Physical and occupational therapy, speech and swallowing assessment, attention to nutrition and weight, and support for mood and cognition all affect daily function in Huntington’s disease more than a milligram change does.

Any chorea treatment change, including a switch between VMAT2 inhibitors, is planned by the neurologist who knows your history. Do not stop or restart these medicines on your own, because movements can return and mood effects can change quickly.

Getting CYP2D6 tested before a dose increase

If your prescriber is considering going above 50 mg a day, the genotype has to come first, so timing is worth planning. An at-home cheek swab kit avoids a separate clinic visit for the collection.

The RPh Labs kit ships within one business day with free shipping both ways, and results come back 7 to 10 business days after the sample reaches our Dallas lab. Self-pay is $299, HSA and FSA eligible, and can be split into four interest-free installments. Insurance including Medicare, Texas Medicaid and Blue Cross Blue Shield of Texas is accepted, with details on our insurance page.

Ask for the report to be sent to your neurologist as well as to you. A result that sits in your email does nothing; a result in the chart before the next dose review is what changes the conversation.

One realistic caveat: a genotype result does not tell you whether tetrabenazine will control your movements, and it does not remove the need for slow titration. It tells your prescriber how high the tetrabenazine dose may go and how carefully to watch on the way there.

Tetrabenazine dose and CYP2D6 FAQ

Is CYP2D6 genotyping required for every tetrabenazine prescription?

No. The label asks for it when the plan is to go above 50 mg per day. Many people are controlled below that and never need the test for this drug. Plenty still choose it, because the same CYP2D6 result applies to antidepressants, codeine, tramadol and other common medicines.

What if I am already taking more than 50 mg without a genotype?

Raise it with your prescriber rather than changing anything yourself. They can order the test and decide whether your current amount fits the label ceilings. Do not reduce or stop doses while you wait, because movements can return and abrupt changes are unpleasant.

Does a CYP2D6 poor metabolizer result mean tetrabenazine will not work?

No, the opposite is closer to the truth. Less drug produces the same active metabolite exposure, so the effect arrives at a lower dose. The label response is a lower ceiling, and your prescriber finds the amount that controls movements within it.

Can a strong CYP2D6 inhibitor be taken with tetrabenazine at all?

Sometimes, with a reduced ceiling and closer monitoring, because a drug like bupropion or paroxetine may be genuinely needed. That decision belongs to the prescriber who can weigh both problems. Never add or stop one of these medicines without telling whoever manages your tetrabenazine.

Is a cheek swab as reliable as a blood sample for CYP2D6?

Yes. DNA from a buccal swab is the same DNA, and our laboratory is CLIA certified and COLA accredited. The collection is what changes, not the result. Our page on cheek swab versus saliva collection explains why the swab is preferred for this panel.

Will my report cover other chorea treatment options?

The panel reports CYP2D6, which is relevant to other VMAT2 inhibitors as well, and reports against more than 240 medications in total. It does not recommend a specific drug. Which chorea treatment suits you depends on your diagnosis, mood history, swallowing, other conditions and your neurologist’s judgment.